Clarity Pharmaceuticals (ASX:CU6) will start a phase three trial of its 64Cu-SAR-bisPSMA diagnostic in patients with recurrent prostate cancer following a successful end-of-phase meeting with the US Food and Drug Administration.
Named AMPLIFY, the trial aims to investigate the ability of 64Cu-SAR-bisPSMA PET/computed tomography to detect the recurrence of prostate cancer, according to a Monday filing with the Australian bourse.
About 220 participants are expected to participate in the trial, with patient recruitment slated for early 2025, the radiopharmaceutical firm said in the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments